CA2893690A1 - Plasmapherese therapeutique pour la galectine-3 - Google Patents

Plasmapherese therapeutique pour la galectine-3 Download PDF

Info

Publication number
CA2893690A1
CA2893690A1 CA2893690A CA2893690A CA2893690A1 CA 2893690 A1 CA2893690 A1 CA 2893690A1 CA 2893690 A CA2893690 A CA 2893690A CA 2893690 A CA2893690 A CA 2893690A CA 2893690 A1 CA2893690 A1 CA 2893690A1
Authority
CA
Canada
Prior art keywords
gal
cancer
inflammation
mammal
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2893690A
Other languages
English (en)
Inventor
Isaac Eliaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eliaz Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2893690A1 publication Critical patent/CA2893690A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'élimination de la gal-3 sérique de la circulation par plasmaphérèse, comprenant au moins en partie une aphérèse donneur, à l'aide d'agents se liant à la gal-3 dans un lit fixe, ou sous une forme facile à éliminer, comme lorsqu'elle est complexée avec des particules magnétiques. Cette méthode, à elle seule, apporte une forte réduction et un fort soulagement de l'inflammation et des fibroses qui peuvent être induites par la gal-3 en circulation. La méthode peut être combinée à l'administration d'agents se liant à la gal-3, tels qu'une pectine d'agrume modifiée, pour réduire davantage les taux de gal-3 non liée, jusqu'au point où la gal-3 dans les tissus n'est plus un problème. Cette méthode peut également être combinée à l'élimination des récepteurs du TNF pour obtenir un traitement efficace contre le cancer.
CA2893690A 2013-01-07 2013-12-27 Plasmapherese therapeutique pour la galectine-3 Abandoned CA2893690A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749517P 2013-01-07 2013-01-07
US61/749,517 2013-01-07
PCT/IB2013/061375 WO2014106803A1 (fr) 2013-01-07 2013-12-27 Plasmaphérèse thérapeutique pour la galectine -3

Publications (1)

Publication Number Publication Date
CA2893690A1 true CA2893690A1 (fr) 2014-07-10

Family

ID=50114430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2893690A Abandoned CA2893690A1 (fr) 2013-01-07 2013-12-27 Plasmapherese therapeutique pour la galectine-3

Country Status (6)

Country Link
EP (1) EP2941284A1 (fr)
AU (2) AU2013371859B2 (fr)
CA (1) CA2893690A1 (fr)
IL (1) IL239448A0 (fr)
MY (2) MY179276A (fr)
WO (1) WO2014106803A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625212A (en) 1969-07-09 1971-12-07 North American Biolog Inc Eliminating mistakes in plasmapheresis
US4531932A (en) 1981-11-27 1985-07-30 Dideco S.P.A. Centrifugal plasmapheresis device
US6245038B1 (en) 1997-01-07 2001-06-12 Helmut Borberg Method for treatment of ophthalmological diseases
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6274566B1 (en) 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
US6462029B1 (en) 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
US20060129082A1 (en) 2002-08-13 2006-06-15 Jacek Rozga Selective plasma exchange therapy
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
WO2010065765A2 (fr) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Capture par affinité de biomarqueurs circulants
BR112014012823A2 (pt) * 2011-12-08 2015-09-29 Isaac Eliaz redução dos níveis de galectina-3 por meio de plasmaferese

Also Published As

Publication number Publication date
IL239448A0 (en) 2015-07-30
MY179276A (en) 2020-11-03
AU2013371859B2 (en) 2018-06-21
AU2016262697A1 (en) 2016-12-15
AU2013371859A1 (en) 2015-07-16
AU2016262697B2 (en) 2018-06-28
MY168406A (en) 2018-11-07
EP2941284A1 (fr) 2015-11-11
WO2014106803A1 (fr) 2014-07-10

Similar Documents

Publication Publication Date Title
US11389477B2 (en) Galectin-3 plasmapheresis therapy
US8764695B2 (en) Reduction of galectin-3 levels by plasmapheresis
US20210138143A1 (en) Plasmapheresis device
DK2788761T3 (en) Reduction of galectin-3 levels by plasma apheresis
AU2016262697B2 (en) Galectin-3 plasmapheresis therapy
NZ624601B2 (en) Reduction of galectin-3 levels by plasmapheresis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180711

FZDE Discontinued

Effective date: 20211001